跳至主要内容
临床试验/ISRCTN36646813
ISRCTN36646813已完成未知

Early treatment of idiopathic Parkinson's disease with dopaminergic agonist piribedil in monotherapy. A two-year randomised, parallel, placebo-controlled study in idiopathic Parkinsonian de novo patients

Institut de Recherches Internationales Servier (France)0 个研究点目标入组 400 人开始时间: 2006年3月31日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Out-patients between 30 to 77 years old, with stage 1 to 3 (Hoehn and Yahr) and less than six weeks of previous L-dopa treatment, with less than 3 months of previous treatment by a dopaminergic agonist

排除标准

  • 1. Patients frequently falling according to unified Parkinson's disease rating scale (UPDRS) II and/or III
  • 2. Prior experience of a dopaminergic complication
  • 3. Prior neurosurgery for PD
  • 4. Previous history of freezing
  • 5. Suspected autosomal juvenile Parkinsonism
  • 6. Atypical Parkinsonian symtoms caused by drugs, metabolic disorders or encephalitis
  • 7. History of psychotic symptoms
  • 8. Poor cognitive performance

研究者

发起方
Institut de Recherches Internationales Servier (France)

相似试验